SCHEMBL5459290

SCHEMBL5459290

CN1CCc2cc(N(C)C)c(S(=O)(=O)c3ccc(Cc4ccc(F)c(C(F)(F)F)c4)cc3)cc2CC1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP2 O75604 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
TP53 P04637 1/20 0.35
GRM2 Q14416 1/20 0.35
TACR2 P21452 2/20 0.33
TACR1 P25103 2/20 0.33
TACR3 P29371 2/20 0.33
GPR52 Q9Y2T5 1/20 0.33
HTR2A P28223 4/20 0.32
HTR2C P28335 4/20 0.32
P2RX7 Q99572 3/20 0.32
DRD2 P14416 2/20 0.32
DRD3 P35462 2/20 0.32
HTR6 P50406 2/20 0.32
AR P10275 1/20 0.32
SLC6A9 P48067 1/20 0.32
KCNH2 Q12809 1/20 0.32
CYP1A2 P05177 1/20 0.32
CYP3A4 P08684 1/20 0.32
CYP2D6 P10635 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5453931 0.92 USP2 (0.36) USP2SMN1; SMN2HTR2AHTR2CP2RX7
SCHEMBL5449066 0.90 PYCR1 (0.38) USP2SMN1; SMN2TP53POLB
SCHEMBL5448741 0.89 USP2 (0.39) USP2SMN1; SMN2HTR2AHTR2CDRD2
SCHEMBL5462437 0.87 KMT2A (0.38) USP2SMN1; SMN2HTR2AHTR2CDRD2
SCHEMBL5450383 0.87 UTS2R (0.38) USP2SMN1; SMN2HTR2AHTR2CDRD2
SCHEMBL5449041 0.86 DRD2 (0.43) USP2SMN1; SMN2HTR2AHTR2CDRD2
SCHEMBL5444653 0.86 HTR2A (0.34) USP2SMN1; SMN2HTR2AHTR2CDRD2
SCHEMBL5445721 0.86 USP2 (0.41) USP2SMN1; SMN2HTR2AHTR2CDRD2
SCHEMBL5457137 0.85 USP2 (0.38) USP2SMN1; SMN2HTR2AHTR2CDRD2
SCHEMBL5448944 0.85 HTR2A (0.36) USP2SMN1; SMN2HTR2AHTR2CP2RX7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070225276-A1 7-Phenylsulfonyl-Tetrahydro-3-Benzazepine Dervatives as Antipsychotic Agents GLAXO GROUP LIMITED (GB) 2007-09-27 US claimed
EP-1687005-A1 7-PHENYLSULFONYL-TETRAHYDRO-3-BENZAZEPINE DERIVATIVES AS ANTIPSYCHOTIC AGENTS GLAXO GROUP LIMITED (GB) 2006-08-09 EP claimed
WO-2005051398-A1 7-PHENYLSULFONYL-TETRAHYDRO-3-BENZAZEPINE DERIVATIVES AS ANTIPSYCHOTIC AGENTS GLAXO GROUP LIMITED (GB) 2005-06-09 WO claimed
US-20070225276-A1 7-Phenylsulfonyl-Tetrahydro-3-Benzazepine Dervatives as Antipsychotic Agents GLAXO GROUP LIMITED (GB) 2007-09-27 US disclosed
EP-1687005-A1 7-PHENYLSULFONYL-TETRAHYDRO-3-BENZAZEPINE DERIVATIVES AS ANTIPSYCHOTIC AGENTS GLAXO GROUP LIMITED (GB) 2006-08-09 EP disclosed
WO-2005051398-A1 7-PHENYLSULFONYL-TETRAHYDRO-3-BENZAZEPINE DERIVATIVES AS ANTIPSYCHOTIC AGENTS GLAXO GROUP LIMITED (GB) 2005-06-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070225276-A1 7-Phenylsulfonyl-Tetrahydro-3-Benzazepine Dervatives as Antipsychotic Agents HTR4, DRD4, SLC6A3 USP2 4595/4885SMN1; SMN2 2075/4885TP53 3353/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.